CT0594CP
PreclinicalBiologic
CT0594CP is one of 22 biologic programs targeting Plasma Cell Leukemia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Plasma Cell Leukemia
#DrugCompanyPhaseTrials
1Alkeran
AApotex Inc.
Approved
Darzalex
Johnson & JohnsonPhase 2
Tecvayli
Johnson & JohnsonPhase 2
Ninlaro
TakedaPhase 2
Decadron
AAspen Global Incorporated
Phase 2
Empliciti
Bristol-Myers SquibbPhase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Kyprolis
VVirionyx Corporation Limited
Phase 2
Mozobil
GGenzyme, a Sanofi Company
Phase 2
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CT0594CP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details